 Paul Christine
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 15 | 2026 | 601 | 3.750 |
Why?
| | Opiate Substitution Treatment | 10 | 2026 | 186 | 3.140 |
Why?
| | Buprenorphine | 7 | 2026 | 190 | 2.090 |
Why?
| | Narcotic Antagonists | 6 | 2026 | 204 | 1.510 |
Why?
| | Naltrexone | 4 | 2026 | 118 | 1.370 |
Why?
| | Buprenorphine, Naloxone Drug Combination | 3 | 2026 | 12 | 1.290 |
Why?
| | Residence Characteristics | 4 | 2018 | 374 | 1.240 |
Why?
| | Methadone | 4 | 2025 | 122 | 1.220 |
Why?
| | Substance Withdrawal Syndrome | 7 | 2026 | 187 | 1.120 |
Why?
| | Analgesics, Opioid | 9 | 2025 | 1142 | 0.980 |
Why?
| | Environment Design | 2 | 2015 | 26 | 0.910 |
Why?
| | Insurance, Health | 2 | 2026 | 308 | 0.880 |
Why?
| | Medicaid | 3 | 2024 | 464 | 0.870 |
Why?
| | Insurance Coverage | 2 | 2024 | 243 | 0.870 |
Why?
| | Food Supply | 2 | 2015 | 85 | 0.860 |
Why?
| | Fentanyl | 5 | 2025 | 127 | 0.850 |
Why?
| | Comparative Effectiveness Research | 2 | 2026 | 167 | 0.810 |
Why?
| | Social Environment | 2 | 2015 | 253 | 0.810 |
Why?
| | Drug Overdose | 5 | 2026 | 370 | 0.680 |
Why?
| | Substance-Related Disorders | 4 | 2026 | 1085 | 0.660 |
Why?
| | Motor Activity | 2 | 2015 | 723 | 0.650 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2017 | 2571 | 0.520 |
Why?
| | Massachusetts | 4 | 2026 | 180 | 0.510 |
Why?
| | Housing | 1 | 2016 | 144 | 0.460 |
Why?
| | Social Class | 1 | 2017 | 265 | 0.450 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1359 | 0.440 |
Why?
| | Economic Development | 1 | 2014 | 2 | 0.430 |
Why?
| | Health Transition | 1 | 2014 | 8 | 0.430 |
Why?
| | Middle Aged | 23 | 2026 | 35892 | 0.420 |
Why?
| | Substance Abuse, Intravenous | 2 | 2026 | 127 | 0.400 |
Why?
| | Atherosclerosis | 1 | 2017 | 408 | 0.390 |
Why?
| | Blood Pressure | 3 | 2025 | 1763 | 0.360 |
Why?
| | Cross-Sectional Studies | 8 | 2026 | 5862 | 0.350 |
Why?
| | Group Processes | 1 | 2012 | 63 | 0.350 |
Why?
| | Body Mass Index | 3 | 2018 | 2417 | 0.350 |
Why?
| | Social Identification | 1 | 2012 | 72 | 0.330 |
Why?
| | Male | 27 | 2026 | 72263 | 0.330 |
Why?
| | Humans | 39 | 2026 | 144298 | 0.320 |
Why?
| | Female | 28 | 2026 | 78137 | 0.310 |
Why?
| | Delayed-Action Preparations | 3 | 2026 | 184 | 0.300 |
Why?
| | Adult | 19 | 2026 | 40408 | 0.300 |
Why?
| | Overweight | 1 | 2014 | 606 | 0.300 |
Why?
| | Patient Participation | 1 | 2013 | 428 | 0.290 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 732 | 0.290 |
Why?
| | Education, Medical | 1 | 2012 | 272 | 0.280 |
Why?
| | Longitudinal Studies | 4 | 2024 | 2940 | 0.280 |
Why?
| | Interrupted Time Series Analysis | 2 | 2025 | 75 | 0.260 |
Why?
| | United States | 9 | 2026 | 15979 | 0.260 |
Why?
| | Students, Medical | 1 | 2012 | 373 | 0.250 |
Why?
| | Socioeconomic Factors | 3 | 2016 | 1320 | 0.250 |
Why?
| | Smoking | 4 | 2018 | 1466 | 0.250 |
Why?
| | Blood Glucose | 1 | 2016 | 2326 | 0.240 |
Why?
| | Cohort Studies | 5 | 2026 | 5948 | 0.240 |
Why?
| | Needle-Exchange Programs | 1 | 2026 | 15 | 0.230 |
Why?
| | Decision Making | 1 | 2013 | 972 | 0.220 |
Why?
| | Xylazine | 1 | 2025 | 15 | 0.220 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2025 | 25 | 0.220 |
Why?
| | Young Adult | 10 | 2026 | 14092 | 0.220 |
Why?
| | Heroin | 1 | 2025 | 29 | 0.220 |
Why?
| | Heroin Dependence | 1 | 2025 | 33 | 0.210 |
Why?
| | Kentucky | 1 | 2024 | 41 | 0.210 |
Why?
| | Mifepristone | 1 | 2024 | 53 | 0.210 |
Why?
| | Diazepam | 1 | 2024 | 33 | 0.210 |
Why?
| | Amphetamine-Related Disorders | 1 | 2024 | 48 | 0.210 |
Why?
| | New York | 1 | 2024 | 127 | 0.210 |
Why?
| | Ohio | 1 | 2024 | 143 | 0.210 |
Why?
| | Hospitals, Urban | 1 | 2024 | 143 | 0.200 |
Why?
| | Observational Studies as Topic | 1 | 2024 | 130 | 0.200 |
Why?
| | Colorado | 4 | 2026 | 4554 | 0.190 |
Why?
| | Benzodiazepines | 1 | 2024 | 168 | 0.190 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1322 | 0.190 |
Why?
| | Central Nervous System Stimulants | 1 | 2024 | 185 | 0.190 |
Why?
| | Naloxone | 1 | 2024 | 131 | 0.190 |
Why?
| | Health Care Costs | 1 | 2026 | 425 | 0.180 |
Why?
| | Abortion, Induced | 1 | 2024 | 110 | 0.180 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2024 | 247 | 0.170 |
Why?
| | Adolescent | 9 | 2025 | 22370 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 496 | 0.170 |
Why?
| | Obesity | 1 | 2014 | 3068 | 0.160 |
Why?
| | Endocarditis, Bacterial | 1 | 2021 | 46 | 0.160 |
Why?
| | Patient-Centered Care | 1 | 2025 | 540 | 0.160 |
Why?
| | Aged, 80 and over | 4 | 2016 | 8265 | 0.160 |
Why?
| | Economic Recession | 1 | 2018 | 4 | 0.140 |
Why?
| | Aged | 7 | 2021 | 25901 | 0.140 |
Why?
| | Unemployment | 1 | 2018 | 41 | 0.140 |
Why?
| | Risk Factors | 3 | 2017 | 10783 | 0.130 |
Why?
| | Research Design | 1 | 2024 | 1128 | 0.130 |
Why?
| | Argentina | 2 | 2014 | 30 | 0.130 |
Why?
| | Prevalence | 3 | 2024 | 2836 | 0.120 |
Why?
| | Smoke-Free Policy | 1 | 2015 | 13 | 0.110 |
Why?
| | Geographic Information Systems | 1 | 2015 | 46 | 0.110 |
Why?
| | Patient Care Team | 1 | 2021 | 689 | 0.110 |
Why?
| | Public Opinion | 1 | 2015 | 62 | 0.110 |
Why?
| | Behavior | 1 | 2015 | 90 | 0.110 |
Why?
| | Models, Psychological | 1 | 2016 | 297 | 0.110 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2016 | 108 | 0.110 |
Why?
| | Pandemics | 1 | 2023 | 1693 | 0.110 |
Why?
| | China | 1 | 2015 | 269 | 0.110 |
Why?
| | Spatio-Temporal Analysis | 1 | 2014 | 39 | 0.110 |
Why?
| | Alcohol Drinking | 2 | 2018 | 823 | 0.110 |
Why?
| | Incidence | 2 | 2024 | 2886 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2016 | 1300 | 0.100 |
Why?
| | Prospective Studies | 2 | 2017 | 7972 | 0.100 |
Why?
| | Amnion | 1 | 2013 | 31 | 0.100 |
Why?
| | Nutrition Surveys | 1 | 2014 | 280 | 0.090 |
Why?
| | Potassium Channels, Calcium-Activated | 1 | 2012 | 11 | 0.090 |
Why?
| | Health Behavior | 1 | 2018 | 786 | 0.090 |
Why?
| | Smoking Cessation | 1 | 2016 | 436 | 0.090 |
Why?
| | HIV Infections | 2 | 2026 | 3148 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2012 | 79 | 0.090 |
Why?
| | Diffusion of Innovation | 1 | 2012 | 95 | 0.090 |
Why?
| | Premature Birth | 2 | 2013 | 375 | 0.090 |
Why?
| | Mental Health | 1 | 2018 | 790 | 0.090 |
Why?
| | Science | 1 | 2012 | 56 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2013 | 369 | 0.080 |
Why?
| | Receptors, Progesterone | 1 | 2012 | 243 | 0.080 |
Why?
| | Physician's Role | 1 | 2012 | 220 | 0.080 |
Why?
| | Hospitalization | 3 | 2026 | 2440 | 0.080 |
Why?
| | Sex Factors | 1 | 2014 | 2103 | 0.070 |
Why?
| | DNA Methylation | 1 | 2013 | 664 | 0.070 |
Why?
| | Physician-Patient Relations | 1 | 2013 | 586 | 0.070 |
Why?
| | Risk Assessment | 1 | 2017 | 3680 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2170 | 0.060 |
Why?
| | Communication | 1 | 2013 | 968 | 0.060 |
Why?
| | Addiction Medicine | 1 | 2026 | 14 | 0.060 |
Why?
| | Monte Carlo Method | 1 | 2026 | 153 | 0.060 |
Why?
| | Philadelphia | 1 | 2024 | 55 | 0.050 |
Why?
| | Hostility | 1 | 2024 | 16 | 0.050 |
Why?
| | Cause of Death | 1 | 2026 | 463 | 0.050 |
Why?
| | Minnesota | 1 | 2023 | 168 | 0.050 |
Why?
| | Hepatitis C | 1 | 2026 | 254 | 0.050 |
Why?
| | Health Surveys | 1 | 2025 | 516 | 0.050 |
Why?
| | Health Policy | 1 | 2024 | 398 | 0.040 |
Why?
| | Heart Rate | 1 | 2025 | 849 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2026 | 11713 | 0.040 |
Why?
| | Propensity Score | 1 | 2021 | 371 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2025 | 912 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 727 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2024 | 850 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1739 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2026 | 1174 | 0.030 |
Why?
| | Pregnancy | 2 | 2024 | 7112 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2025 | 17104 | 0.030 |
Why?
| | Educational Status | 1 | 2018 | 463 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2021 | 1028 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2024 | 1098 | 0.030 |
Why?
| | Primary Health Care | 1 | 2026 | 1728 | 0.030 |
Why?
| | Mexico | 1 | 2015 | 234 | 0.030 |
Why?
| | Lipids | 1 | 2018 | 702 | 0.020 |
Why?
| | Quality of Life | 1 | 2025 | 3180 | 0.020 |
Why?
| | Receptors, Oxytocin | 1 | 2013 | 20 | 0.020 |
Why?
| | Tobacco Smoke Pollution | 1 | 2015 | 227 | 0.020 |
Why?
| | Indians, South American | 1 | 2012 | 23 | 0.020 |
Why?
| | CpG Islands | 1 | 2013 | 161 | 0.020 |
Why?
| | Labor, Obstetric | 1 | 2013 | 67 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2013 | 195 | 0.020 |
Why?
| | Cation Transport Proteins | 1 | 2013 | 118 | 0.020 |
Why?
| | Genetic Loci | 1 | 2013 | 260 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2321 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2012 | 212 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2012 | 393 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 749 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2013 | 6387 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2018 | 1148 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 612 | 0.020 |
Why?
| | Gestational Age | 1 | 2013 | 980 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1557 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2013 | 1244 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2013 | 668 | 0.020 |
Why?
| | Fetus | 1 | 2012 | 800 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1843 | 0.020 |
Why?
| | Exercise | 1 | 2018 | 2183 | 0.020 |
Why?
| | Placenta | 1 | 2013 | 781 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2013 | 1762 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2134 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2348 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 6035 | 0.010 |
Why?
|
|
Christine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|